KRAS and neoplasm: The tumor-suppressive effects of TGFβ signaling can be modeled in a series of ‘tumor-progression organoids (TPO)’ in which PDOs from healthy intestine are transformed in a stepwise fashion by CRISPR-CAS9-mediated introduction of mutations in APC, KRAS, TP53, and SMAD4 [20].